Adam Levy
Net worth: 117 494 $ as of 2026-06-29
Net worth: 117 494 $ as of 2026-06-29
Adam D.
Levy is currently Director at Vesselon, Inc. and will be Chief Financial Officer at Acrivon Therapeutics, Inc. starting in 2025.
Former roles include Executive Director-Investor Relations at Gilead Sciences, Inc. from 2016 to 2020, EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc. in 2021, Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc. from 2021 to 2022, and Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. from 2022 to 2023.
Education includes an MBA from Kellogg School of Management and undergraduate studies at the University of Illinois At Urbana–Champaign.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-03 | 66,008 ( 0.15% ) | 117 494 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Director of Finance/CFO | 2025-03-31 |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | 2022-12-31 |
| TURG POIN | Investor Relations Contact | 2021-12-31 |
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 2021-12-30 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2019-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Health Technology |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
Select your edition
All financial news and data tailored to specific country editions